ACC: Fujifilm highlights Synapse 3D advanced viz software
Fujifilm Medical Systems showcased a 3D advanced visualization package called Synapse 3D for integration into its Synapse cardiovascular informatics portfolio, at the 59th annual American College of Cardiology (ACC) Scientific Session in Atlanta this week.
The product offers cardiovascular-specific image analysis applications, such as CT angiography, cardiac function analysis for CT/MR and cardiac fusion for CT/nuclear medicine and coronary angiography. Other advanced analysis and visualization tools available include calcium scoring, 3D ultrasound and 3D/4D reconstruction.
Synapse 3D is pending FDA 510(k) clearance and is not yet available for sale in the U.S.
"This product will give cardiologists integration between a total cardiology solution and an imaging component that will enable them to look at 3D applications within an uninterrupted workflow," Debra Umlauft, product line manager for advanced visualization, told Cardiovascular Business News.
Cardiologists will be able to access all prior imaging studies of patients and can switch from modality to modality and even from vendor to vendor as the system is web-based.
Synapse 3D performs vessel analysis, plaque analysis, volume measurements and stenosis measurements, which can be preprogrammed to occur upon boot up or they can be performed with one click, Umlauft said. There also is an application to create a virtual angiogram with the CT dataset and correlate that with pre- or post-PCI.
The company expects to be able to commercially market Synapse 3D in the U.S. by mid-2010, according to Aaron Waitz, vice president of clinical product development.
The product offers cardiovascular-specific image analysis applications, such as CT angiography, cardiac function analysis for CT/MR and cardiac fusion for CT/nuclear medicine and coronary angiography. Other advanced analysis and visualization tools available include calcium scoring, 3D ultrasound and 3D/4D reconstruction.
Synapse 3D is pending FDA 510(k) clearance and is not yet available for sale in the U.S.
"This product will give cardiologists integration between a total cardiology solution and an imaging component that will enable them to look at 3D applications within an uninterrupted workflow," Debra Umlauft, product line manager for advanced visualization, told Cardiovascular Business News.
Cardiologists will be able to access all prior imaging studies of patients and can switch from modality to modality and even from vendor to vendor as the system is web-based.
Synapse 3D performs vessel analysis, plaque analysis, volume measurements and stenosis measurements, which can be preprogrammed to occur upon boot up or they can be performed with one click, Umlauft said. There also is an application to create a virtual angiogram with the CT dataset and correlate that with pre- or post-PCI.
The company expects to be able to commercially market Synapse 3D in the U.S. by mid-2010, according to Aaron Waitz, vice president of clinical product development.